Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]
The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2015-02-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | http://f1000research.com/articles/4-34/v1 |
id |
doaj-54313bb2893248b4bd68565fbbb7dc69 |
---|---|
record_format |
Article |
spelling |
doaj-54313bb2893248b4bd68565fbbb7dc692020-11-25T03:50:03ZengF1000 Research LtdF1000Research2046-14022015-02-01410.12688/f1000research.6110.16544Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]Veljko Veljkovic0Philippe M. Loiseau1Bruno Figadere2Sanja Glisic3Nevena Veljkovic4Vladimir R. Perovic5David P. Cavanaugh6Donald R. Branch7Center for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, SerbiaAntiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy Université Paris-Sud, Rue Jean-Baptiste Clément, F 92290- Chatenay-Malabry, FranceAntiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy Université Paris-Sud, Rue Jean-Baptiste Clément, F 92290- Chatenay-Malabry, FranceCenter for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, SerbiaCenter for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, SerbiaCenter for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, SerbiaBench Electronics, Bradford Dr., Huntsville, AL, 35801, USACanadian Blood Services, Center for Innovation, 67 College Street, Toronto, Ontario, M5G 2M1, CanadaThe ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection. We performed a repurposing screen of 6438 drugs from DrugBank using this criterion and selected 267 approved and 382 experimental drugs as candidates for treatment of EVD including 15 anti-malarial drugs and 32 antibiotics. An open source Web server allowing screening of molecular libraries for candidate drugs for treatment of EVD was also established.http://f1000research.com/articles/4-34/v1Antimicrobials & Drug ResistanceBioinformaticsTropical & Travel-Associated DiseasesVirology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Veljko Veljkovic Philippe M. Loiseau Bruno Figadere Sanja Glisic Nevena Veljkovic Vladimir R. Perovic David P. Cavanaugh Donald R. Branch |
spellingShingle |
Veljko Veljkovic Philippe M. Loiseau Bruno Figadere Sanja Glisic Nevena Veljkovic Vladimir R. Perovic David P. Cavanaugh Donald R. Branch Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s] F1000Research Antimicrobials & Drug Resistance Bioinformatics Tropical & Travel-Associated Diseases Virology |
author_facet |
Veljko Veljkovic Philippe M. Loiseau Bruno Figadere Sanja Glisic Nevena Veljkovic Vladimir R. Perovic David P. Cavanaugh Donald R. Branch |
author_sort |
Veljko Veljkovic |
title |
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s] |
title_short |
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s] |
title_full |
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s] |
title_fullStr |
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s] |
title_full_unstemmed |
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s] |
title_sort |
virtual screen for repurposing approved and experimental drugs for candidate inhibitors of ebola virus infection [v1; ref status: indexed, http://f1000r.es/51s] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2015-02-01 |
description |
The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection. We performed a repurposing screen of 6438 drugs from DrugBank using this criterion and selected 267 approved and 382 experimental drugs as candidates for treatment of EVD including 15 anti-malarial drugs and 32 antibiotics. An open source Web server allowing screening of molecular libraries for candidate drugs for treatment of EVD was also established. |
topic |
Antimicrobials & Drug Resistance Bioinformatics Tropical & Travel-Associated Diseases Virology |
url |
http://f1000research.com/articles/4-34/v1 |
work_keys_str_mv |
AT veljkoveljkovic virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s AT philippemloiseau virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s AT brunofigadere virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s AT sanjaglisic virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s AT nevenaveljkovic virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s AT vladimirrperovic virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s AT davidpcavanaugh virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s AT donaldrbranch virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s |
_version_ |
1724492633192005632 |